PE20140391A1 - 1H-PIRAZOLE-5-SODIUM OLATE SUBSTITUTE - Google Patents

1H-PIRAZOLE-5-SODIUM OLATE SUBSTITUTE

Info

Publication number
PE20140391A1
PE20140391A1 PE2013000943A PE2013000943A PE20140391A1 PE 20140391 A1 PE20140391 A1 PE 20140391A1 PE 2013000943 A PE2013000943 A PE 2013000943A PE 2013000943 A PE2013000943 A PE 2013000943A PE 20140391 A1 PE20140391 A1 PE 20140391A1
Authority
PE
Peru
Prior art keywords
pirazole
compound
sodium
substitute
morfolin
Prior art date
Application number
PE2013000943A
Other languages
Spanish (es)
Inventor
Hans-Christian Militzer
Jorg Gries
Stefan Koep
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of PE20140391A1 publication Critical patent/PE20140391A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

REFERIDA AL COMPUESTO 1- 6- MORFOLIN-4-IL PIRIMIDIN-4-IL -4- 1H-1,2,3-TRIAZOL-1-IL -1H-PIRAZOL-5-OLATO SODICO DE FORMULA (II) EN SU FORMA CRISTALINA. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION QUE CONSISTE EN HACER REACCIONAR EL COMPUESTO 1-[6-(MORFOLIN-4-IL)PIRIMIDIN-4-IL]-4-(1H-1,2,3-TRIAZOL-1-IL)-1H-PIRAZOL-5-OL EN UN DISOLVENTE CON HIDROXIDO DE SODIO O SODA CAUSTICA ACUOSA O UNA SAL SODICA, CON LA ADICION DE UNA BASE TAL COMO TRIETILAMINA. DICHO COMPUESTO ES UTIL EN EL TRATAMIENTO DE ENFERMEDADES CARDIO-CIRCULATORIAS, ANEMIA, ENFERMEDADES RENALES CRONICAS E INSUFECIENCIA RENALREFERRING TO THE COMPOUND 1- 6- MORFOLIN-4-IL PYRIMIDIN-4-IL -4- 1H-1,2,3-TRIAZOL-1-IL-1H-PIRAZOLE-5-OLATE SODIUM OF FORMULA (II) IN ITS FORM CRYSTAL. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION AND TO A PREPARATION PROCEDURE WHICH CONSISTS OF REACTING THE COMPOUND 1- [6- (MORFOLIN-4-IL) PIRIMIDIN-4-IL] -4- (1H-1,2,3-TRIAZOLE -1-IL) -1H-PIRAZOL-5-OL IN A SOLVENT WITH SODIUM HYDROXIDE OR AQUEOUS CAUSTIC SODA OR A SODIUM SALT, WITH THE ADDITION OF A BASE SUCH AS TRIETILAMINE. SAID COMPOUND IS USEFUL IN THE TREATMENT OF CARDIO-CIRCULATORY DISEASES, ANEMIA, CHRONIC KIDNEY DISEASES AND KIDNEY INSUFFICIENCY

PE2013000943A 2010-11-18 2011-11-15 1H-PIRAZOLE-5-SODIUM OLATE SUBSTITUTE PE20140391A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102010044131A DE102010044131A1 (en) 2010-11-18 2010-11-18 Substituted sodium 1H-pyrazole-5-olate

Publications (1)

Publication Number Publication Date
PE20140391A1 true PE20140391A1 (en) 2014-03-29

Family

ID=44999768

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2013000943A PE20140391A1 (en) 2010-11-18 2011-11-15 1H-PIRAZOLE-5-SODIUM OLATE SUBSTITUTE
PE2017002012A PE20180324A1 (en) 2010-11-18 2011-11-15 1H-PIRAZOLE-5-SODIUM OLATE SUBSTITUTE

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2017002012A PE20180324A1 (en) 2010-11-18 2011-11-15 1H-PIRAZOLE-5-SODIUM OLATE SUBSTITUTE

Country Status (45)

Country Link
US (2) US8653074B2 (en)
EP (1) EP2640718B8 (en)
JP (1) JP5918779B2 (en)
KR (2) KR101984317B1 (en)
CN (2) CN103270031B (en)
AP (1) AP3429A (en)
AR (1) AR083887A1 (en)
AU (1) AU2011331305B2 (en)
BR (1) BR112013012223B1 (en)
CA (1) CA2818002C (en)
CL (1) CL2013001390A1 (en)
CO (1) CO6741155A2 (en)
CR (1) CR20130196A (en)
CU (1) CU20130072A7 (en)
CY (1) CY1120375T1 (en)
DE (1) DE102010044131A1 (en)
DK (1) DK2640718T3 (en)
DO (1) DOP2013000096A (en)
EA (1) EA023103B1 (en)
EC (1) ECSP13012627A (en)
ES (1) ES2675580T3 (en)
GT (1) GT201300125A (en)
HK (2) HK1188782A1 (en)
HR (1) HRP20180993T1 (en)
HU (1) HUE038024T2 (en)
IL (1) IL226192A (en)
JO (1) JOP20110347B1 (en)
LT (1) LT2640718T (en)
MA (1) MA34671B1 (en)
MX (1) MX347670B (en)
MY (1) MY167219A (en)
NZ (1) NZ610614A (en)
PE (2) PE20140391A1 (en)
PL (1) PL2640718T3 (en)
PT (1) PT2640718T (en)
RS (1) RS57599B1 (en)
SG (1) SG189975A1 (en)
SI (1) SI2640718T1 (en)
TN (1) TN2013000215A1 (en)
TR (1) TR201806652T4 (en)
TW (1) TWI516485B (en)
UA (1) UA112422C2 (en)
UY (1) UY33736A (en)
WO (1) WO2012065967A1 (en)
ZA (1) ZA201304430B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006050516A1 (en) 2006-10-26 2008-04-30 Bayer Healthcare Ag New pyrazol-3-one compounds are hypoxia-inducible transcription factor-prolyl-4-hydroxylase inhibitors useful e.g. to treat and/or prophylaxis heart-circulation diseases, heart failure, anemia, chronic kidney diseases and renal failure
DE102010044131A1 (en) * 2010-11-18 2012-05-24 Bayer Schering Pharma Aktiengesellschaft Substituted sodium 1H-pyrazole-5-olate
MY184577A (en) * 2012-05-08 2021-04-06 Bayer Pharma AG Method for the preparation of triazole compounds
MX2016004628A (en) * 2013-10-17 2016-08-01 Bayer Pharma AG Pharmaceutical dosage forms containing sodium-1-[6-(morpholin-4-y l)pyrimidin-4-yl]-4-(1h-1,2,3-triazol-1-yl)-1h-pyrazol-5-olate.
EP3197442B1 (en) 2014-09-26 2019-07-03 The Cleveland Clinic Foundation Treating and preventing disease with tma and tmao lowering agents
CL2015003047A1 (en) * 2015-10-15 2016-06-17 Univ Chile Ex vivo method to detect acute renal injury early in critically ill patients, which includes mediciom in a sample of three proteins as biomarkers, fibroblastic growth factor 23, klotho and erythropoietin
WO2018149929A1 (en) * 2017-02-16 2018-08-23 Bayer Pharma Aktiengesellschaft Combination of reporter gene assays and transcriptional analysis
EP3888684A1 (en) * 2020-03-31 2021-10-06 Bayer Animal Health GmbH Composition having improved voluntary acceptance

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1519069A (en) 1966-04-13 1968-03-29 Geigy Ag J R Sulfanilamide derivatives and their preparation
GR63123B (en) 1975-12-11 1979-09-11 Lilly Co Eli Preparation process of novel 1,4-diphenyl-3-pyrazolin-5-ones
US4075003A (en) 1975-12-11 1978-02-21 Eli Lilly And Company Novel herbicidal method utilizing 1,4-diphenyl-3-pyrazolin-5-ones
PL103509B1 (en) 1976-09-20 1979-06-30 Lilly Co Eli A WORMHOUSE
US4663327A (en) 1984-05-23 1987-05-05 Bayer Aktiengesellschaft 1-heteroaryl-4-aryl-pyrazolin-5-ones
DE3443308A1 (en) 1984-11-28 1986-05-28 Bayer Ag, 5090 Leverkusen 1-HETEROARYL-4-ARYL-PYRAZOLIN-5-ONE FOR USE AS A MEDICINAL PRODUCT
DE3527157A1 (en) 1985-07-30 1987-02-12 Bayer Ag 1-HETEROARYL-4-ARYL-PYRAZOLE DERIVATIVES
DE4204919A1 (en) 1992-02-19 1993-08-26 Bayer Ag METHOD FOR PRODUCING 2-CHLORINE-5-ALKYLAMINOMETHYL PYRIDINE
JPH0735361B2 (en) * 1993-09-09 1995-04-19 日産化学工業株式会社 Hydrazone derivative and method for producing the same
FR2725988B1 (en) 1994-10-24 1997-01-24 Roussel Uclaf NEW DERIVATIVES OF PYRAZOLONES AND ACID PYRAZOLES, THEIR PROCESS OF PREPARATION, THE NEW INTERMEDIARIES OBTAINED, THEIR APPLICATION AS MEDICINAL PRODUCTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
JPH10306077A (en) 1997-05-07 1998-11-17 Daiichi Rajio Isotope Kenkyusho:Kk Bipyrazole derivative, and medicine and reagent consisting essentially thereof
DE19909237A1 (en) 1999-03-03 2000-09-07 Merck Patent Gmbh Pyrazol-3-one derivatives
US6878729B2 (en) 2001-05-04 2005-04-12 The Procter & Gamble Company Medicinal uses of dihydropyrazoles
CA2447593C (en) 2001-05-15 2014-07-08 Ortho-Mcneil Pharmaceutical, Inc. Ex-vivo priming for generating cytotoxic t lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease
CA2446864C (en) 2001-05-16 2011-02-15 Vertex Pharmaceuticals Incorporated Inhibitors of src and other protein kinases
BR0212044A (en) 2001-09-21 2004-08-17 Solvay Pharm Bv Compounds, pharmaceutical compositions, method of preparation thereof, and use of a compound
US7569592B2 (en) 2001-12-18 2009-08-04 Merck & Co., Inc. Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
US20040176372A1 (en) 2002-03-01 2004-09-09 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
UY27813A1 (en) * 2002-05-31 2003-12-31 Smithkline Beecham Corp PEPTIDE-DISFORMILASE INHIBITORS
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
CA2522441A1 (en) 2003-03-27 2004-10-14 Emory University Hif-1 inhibitors
CA2520870A1 (en) 2003-04-03 2004-10-21 Merck & Co., Inc. Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5
AU2004236690A1 (en) 2003-05-01 2004-11-18 Panacea Pharmaceuticals, Inc. Methods of treating ischemic related conditions
CN1842332A (en) * 2003-06-30 2006-10-04 Hif生物公司 Compounds, compositions and methods
CA2530679A1 (en) 2003-06-30 2005-04-07 Hif Bio, Inc. Compounds for treating angiogenesis
CA2614068A1 (en) 2004-06-29 2006-08-24 Massachusetts Institute Of Technology Methods and compositions related to the modulation of intercellular junctions
DE102008020113A1 (en) 2008-04-23 2009-10-29 Bayer Schering Pharma Aktiengesellschaft Substituted dihydropyrazolones and their use
MX2007011280A (en) 2005-03-16 2007-11-15 Aventis Pharma Inc Dipyrazoles as central nervous system agents.
DE102005019712A1 (en) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone and its use
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
WO2007121687A1 (en) 2006-04-26 2007-11-01 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China 4-methyl-1h-diaryl pyrazole derivatives and their uses as medicament
DE102006050513A1 (en) 2006-10-26 2008-04-30 Bayer Healthcare Ag New substituted dihydropyrazolone derivatives are hypoxia-inducible transcription factor-prolyl-4-hydroxylase inhibitors useful to treat/prevent e.g. cardiovascular diseases, heart-circulation diseases, heart failure and anemia
DE102006050515A1 (en) 2006-10-26 2008-04-30 Bayer Healthcare Ag New substituted dipyridiyl-dihydropyrazolone derivatives are hypoxia-inducible transcription factor-prolyl-4-hydroxylase inhibitors useful to treat/prevent e.g. cardiovascular diseases, heart-circulation diseases, heart failure and anemia
DE102006050516A1 (en) 2006-10-26 2008-04-30 Bayer Healthcare Ag New pyrazol-3-one compounds are hypoxia-inducible transcription factor-prolyl-4-hydroxylase inhibitors useful e.g. to treat and/or prophylaxis heart-circulation diseases, heart failure, anemia, chronic kidney diseases and renal failure
DE102010044131A1 (en) * 2010-11-18 2012-05-24 Bayer Schering Pharma Aktiengesellschaft Substituted sodium 1H-pyrazole-5-olate

Also Published As

Publication number Publication date
JP5918779B2 (en) 2016-05-18
US20120129857A1 (en) 2012-05-24
GT201300125A (en) 2017-07-26
PL2640718T3 (en) 2018-08-31
KR101984317B1 (en) 2019-05-30
HUE038024T2 (en) 2018-09-28
AU2011331305B2 (en) 2016-06-02
CU20130072A7 (en) 2013-09-27
AP2013006922A0 (en) 2013-06-30
CN103270031B (en) 2015-06-17
TR201806652T4 (en) 2018-06-21
SG189975A1 (en) 2013-06-28
UY33736A (en) 2012-06-29
EP2640718A1 (en) 2013-09-25
MX2013004797A (en) 2013-06-28
EP2640718B1 (en) 2018-03-28
MA34671B1 (en) 2013-11-02
NZ610614A (en) 2015-05-29
EA201390703A1 (en) 2013-12-30
CA2818002A1 (en) 2012-05-24
IL226192A0 (en) 2013-07-31
WO2012065967A1 (en) 2012-05-24
LT2640718T (en) 2018-07-10
RS57599B1 (en) 2018-11-30
ES2675580T3 (en) 2018-07-11
DE102010044131A1 (en) 2012-05-24
CA2818002C (en) 2019-01-15
EA023103B1 (en) 2016-04-29
CR20130196A (en) 2013-08-06
PE20180324A1 (en) 2018-02-13
ZA201304430B (en) 2014-12-23
AP3429A (en) 2015-09-30
BR112013012223A2 (en) 2020-03-10
MY167219A (en) 2018-08-14
HK1210776A1 (en) 2016-05-06
US9533972B2 (en) 2017-01-03
IL226192A (en) 2016-06-30
PT2640718T (en) 2018-07-04
KR20180023043A (en) 2018-03-06
UA112422C2 (en) 2016-09-12
TWI516485B (en) 2016-01-11
TN2013000215A1 (en) 2014-11-10
BR112013012223B1 (en) 2021-06-29
ECSP13012627A (en) 2013-07-31
JOP20110347B1 (en) 2021-08-17
CN103270031A (en) 2013-08-28
TW201307328A (en) 2013-02-16
MX347670B (en) 2017-05-03
EP2640718B8 (en) 2018-06-27
CL2013001390A1 (en) 2014-04-04
CN104650047A (en) 2015-05-27
SI2640718T1 (en) 2018-08-31
HK1188782A1 (en) 2014-05-16
KR20130131335A (en) 2013-12-03
DK2640718T3 (en) 2018-07-16
CY1120375T1 (en) 2019-07-10
HRP20180993T1 (en) 2018-08-10
US8653074B2 (en) 2014-02-18
DOP2013000096A (en) 2013-06-15
CO6741155A2 (en) 2013-08-30
AR083887A1 (en) 2013-03-27
AU2011331305A1 (en) 2013-06-06
US20130310381A1 (en) 2013-11-21
JP2014500877A (en) 2014-01-16

Similar Documents

Publication Publication Date Title
PE20140391A1 (en) 1H-PIRAZOLE-5-SODIUM OLATE SUBSTITUTE
BR112012026338A2 (en) new 3,3-dimethyl tetrahydroquinoline derivatives
CY1118478T1 (en) AZAZIDAZOL OR DIAZANDAZOLI TYPE PRODUCTS FOR TREATMENT OF PAIN
HN2012000182A (en) PHARMACEUTICAL FORMULATION
PE20141822A1 (en) INHIBITOR OF APOPTOSIS SIGNAL REGULATORY KINASE
ECSP11011494A (en) SOLID PREPARATION
BR112012013847A2 (en) new indolinone cyclopropane derivatives
MX344473B (en) Semisolid aqueous pharmaceutical composition containing tapentadol.
MX2010006787A (en) Halogenated analogues of anti-fibrotic agents.
DOP2011000245A (en) DERIVATIVES OF TIADIAZOLES AND OXADIAZOLS, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS
BR112013020419A2 (en) pyrazole-derived microbicides
CO7141429A2 (en) New pyrazole compounds
BR112013017442A2 (en) use of compounds, cleaning or washing composition, compound, and process for preparing compounds
AR114134A2 (en) 11- (2-PYRROLIDIN-1-IL-ETOXY) -14,19-DIOXA-5,7,26-TRIAZA-TETRACICLO MALEATE SALT [19.3.1.1 (2.6) .1 (8.12)] HEPTACOSE-1 (25), 2 (26), 3,5,8,10,12 (27), 16,21,23-DECAENE
AR114133A2 (en) 11- (2-PYRROLIDIN-1-IL-ETOXY) -14,19-DIOXA-5,7,26-TRIAZA-TETRACICLO CITRATE SALT [19.3.1.1 (2.6) .1 (8.12)] HEPTACOSE-1 (25), 2 (26), 3,5,8,10,12 (27), 16,21,23-DECAENE
BR112014001299A2 (en) crystalline form of 4-tert-butyl-n- [4-chloro-2- (1-oxo-pyridine-4-carbonyl) -phenyl] -benzenesulfonamide sodium salt
ECSP11010856A (en) SOLID PHARMACEUTICAL COMPOSITION
UY32496A (en) DERIVATIVES OF N - [(6-AZA-BICYCLE [3.2.1] OCT-5-IL) -ARIL-METHYL) -HETEROBENZAMIDE, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS.
EP2319514A4 (en) Stable aqueous solution composition containing sulfonamide compound
BR112013024314A2 (en) quinoline derivatives as fungicides
BR112012008952A2 (en) microbicides
WO2007129184A3 (en) An improved process for the preparation of phenytoin sodium
AR119050A2 (en) 3,6-DICHLOROSALICYLIC ACID COMPOUNDS AND RELATED SYNTHESIS PROCESSES
AR109745A2 (en) DERIVATIVE OF 4-PYRIMIDINSULFAMIDE
UA100654C2 (en) Disodium salt of 2-(pyridine-4-ylthio)succinic acid exhibiting antioxidant, antidepressant and nootropic activity

Legal Events

Date Code Title Description
FC Refusal
FG Grant, registration